Substituting less costly nonbranded drugs to lower patients’ out-of-pocket costs is one possible solution to the complex issue of poor adherence.
Under a proposed rule, generic-drug manufacturers will be able to update their product labeling prior to FDA review, accelerating the dissemination of safety information.